Analysts' Actions: GRPN RAX JAZZ PCLN MGM

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Cubist Pharmaceuticals ( CBST) rated new Buy at Goldman. Stock also placed on the Conviction List. $54 price target. CXA will likely be the company's next big growth driver.

CVS Caremark ( CVS) upgraded at BMO from Market Perform to Outperform, BMO Capital said. $53 price target. Company should see improved margins and earnings power in the coming quarters.

Dril-Quip ( DRQ) downgraded at BofA/Merrill from Buy to Underperform, Bank of America/Merrill Lynch said. Valuation call, based on a $79 price target.

FirstEnergy ( FE) downgraded at UBS to Neutral from Buy, UBS said. $49 price target. Standing aside on opaque outlook.

First Energy downgraded at BMO from Outperform to Market Perform, BMO Capital said. $48 price target. Management has limited earnings visibility.

Fossil ( FOSL) downgraded at Citigroup to Neutral from Buy, Citigroup said. $100 price target. Valuation call after rally on quarterly results.

Groupon ( GRPN) downgraded at Sterne Agee from Buy to Neutral, Sterne Agee said. Estimates also cut, as growth appears to be slowing.

Halliburton ( HAL) upgraded to buy at TheStreet Ratings.

Jive Software ( JIVE) downgraded at Citigroup to Neutral from Buy, Citigroup said. $21 price target. Thesis not playing out as fast as we'd hoped.

Jack Henry ( JKHY) upgraded at Wells from Market Perform to Outperform, Wells Fargo said. Company has a strong balance sheet and the spending environment is improving.

MGE Energy ( MGEE) upgraded at DA Davidson from Underperform to Neutral, DA Davidson said. Valuation call, based on a $48.50 price target.

MGM ( MGM) downgraded to sell at TheStreet Ratings.

VeriFone ( PAY) downgraded at UBS to Neutral from Buy, UBS said. $41 price target. Catalysts played out.

Par Pharmaceutical ( PRX) downgrade at UBS to Neutral from Buy, UBS said. $58 price target. Valuation call given current TPG offer price.

Rackspace ( RAX) upgraded at Pacific Crest to Outperform, Pacific Crest said. $62 price target. Company is realizing higher margins.

Sapient ( SAPE) downgraded at Wells from Outperform to Market Perform, Wells Fargo said. Company is seeing slower growth in its Nitro segment.

Vectren ( VVC) rated new Buy at Brean. $36 price target. Company has a solid yield and can deliver consistent growth over the long term.

Windstream ( WIN) downgraded at Nomura from Neutral to Reduce, Nomura said. $8.50 price target. Company is leveraged to macro risks and could face increased competition.

STOCK COMMENTS / EPS CHANGES

Jazz Pharmaceuticals ( JAZZ) numbers increased at Lazard. JAZZ estimates were raised through 2013, Lazard said. Company is growing across the board and boosted guidance. Buy rating and new $76 price target.

MGM Resorts ( MGM) numbers cut at Topeka. Shares of MGM now seen reaching $16, according to Topeka Capital. Estimates also reduced, given slower expected growth in Las Vegas.

Priceline.com ( PCLN) numbers lowered at Citigroup. Shares of PCLN now seen reaching $740, Citigroup said. Estimates also lowered on lower 3Q guide. Buy rating.

Priceline.com estimates, target cut at Benchmark. PCLN estimates were reduced through 2013, Benchmark said. Company is realizing decelerating growth. Buy rating and new $725 price target.

>To submit a news tip, email: tips@thestreet.com.

READERS ALSO LIKE:


Follow TheStreet on Twitter and become a fan on Facebook.
This article was written by a staff member of TheStreet.

If you liked this article you might like

Dow Soars Over 250 Points to Post Its Fourth Straight Day of Gains
Inflation, Chipotle, Credit Suisse and Sam's Club - 5 Things You Must Know

Inflation, Chipotle, Credit Suisse and Sam's Club - 5 Things You Must Know

Will Inflation Set Stocks' Hearts Aflutter or Be a Poison Arrow? -- Market Recon

Will Inflation Set Stocks' Hearts Aflutter or Be a Poison Arrow? -- Market Recon

The Really Big Money Rushes to Super Bowl

The Really Big Money Rushes to Super Bowl

What Warren Buffett's Two Successors Could Still Learn From the Billionaire

What Warren Buffett's Two Successors Could Still Learn From the Billionaire